CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...
CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at ...
Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...
Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback